New Haven, Conn.-based Alexion Pharmaceuticals has released data from studies related to the Phase 3 ARISE trial of Kanuma. Kanuma, or sebelipase alfa, is a drug treatment for lysosomal acid lipase deficiency.
Here's what you need to know:
1. Two-thirds of patients treated with Kanuma for 52 weeks experienced reduced liver fibrosis.
2. Half of patients treated with Kanuma for 52 weeks experienced at least a two-stage reduction in liver fibrosis.
3. Kanuma-treated patients also experienced improvements in alanine aminotransferase, LDL cholesterol and liver fat content.